Novartis gains U.S. approval for delayed MS drug

ZURICH (Reuters) – Novartis’s Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market.


Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *